The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2015 | Final analysis of the phase 4 EXELS trial in high-risk patients with essential thrombocythemia
At the 20th Congress of the European Hematology Association (EHA), Claire Harrison, MD, DM, FRCP, FRCPath, of Guy’s and St Thomas’ NHS Foundation Trust, London, UK, discusses the final results of the Evaluation of Xagrid® Efficacy and Long-term Safety (EXELS) trial. EXELS is an observational phase 4 trial that compared safety, pregnancy outcomes, and efficacy, measured by incidence of thrombohaemorrhagic events and platelet reduction, of anagrelide compared with other cytoreductive therapies in high-risk patients with essential thrombocythemia.
